首页|前列腺癌局灶治疗联合免疫治疗的研究进展

前列腺癌局灶治疗联合免疫治疗的研究进展

扫码查看
前列腺癌(PCa)是当今全球男性第二常见的恶性肿瘤,且发病率日益增高.局灶治疗不仅能引起肿瘤坏死,还能促进肿瘤来源的自身抗原释放到血液循环中,刺激宿主免疫系统对肿瘤产生良好的抗肿瘤免疫作用.然而,单一的局部治疗可能难以完全消融癌细胞,容易导致病灶区域复发.免疫疗法通过增强机体免疫应答,杀死肿瘤细胞,抑制免疫逃逸.近年来发现,局灶治疗与免疫治疗相结合时治疗效果更好,可以增强初始免疫反应,可用于低中危局限性PCa.本文主要从PCa的病因和疾病进展,PCa局灶治疗选择,PCa局灶治疗联合免疫治疗的优势与展望等方面进行综述,旨在为PCa的治疗策略提供新的思路.
Focal therapy combined with immunotherapy for prostate cancer:Advances in studies
Prostate cancer(PCa)ranks as the second most prevalent malignancy among males worldwide at present,and its prevalence keeps rising.Focal therapy not only results in tumor necrosis but also encourages the release of autoantigens originating from the tumor into the bloodstream and activates the host immune system to effectively fight the tumor.However,focal therapy alone may not achieve the total ablation of cancer cells and may cause locoregional recurrence.Immunotherapy,by boosting the body's immune re-sponse,destroys tumor cells and prevents immune escape.Recent studies show that focal therapy combined with immunotherapy can produce a better clinical efficacy by enhancing the initial immune response,especially for low-to intermediate-risk confined PCa.This article offers some fresh perspectives on the management of PCa by reviewing the etiology and progression of the malignancy,focal ther-apeutic options,and advantages and vista of focal therapy combined with immunotherapy.

prostate cancerfocal therapyimmunotherapyoncology

张传国、李卫胜、郑聪、何文强

展开 >

河南中医药大学第一附属医院泌尿外科,河南 郑州 450003

河南中医药大学第一临床医学院,河南 郑州 450003

前列腺癌 局灶治疗 免疫治疗 肿瘤学

河南省中医药科学研究专项课题河南省中医药科学研究专项课题河南省2024年科技发展计划

2023ZXZX10892024ZY2045242102311103

2024

中华男科学杂志
南京军区南京总医院

中华男科学杂志

CSTPCD
影响因子:1.052
ISSN:1009-3591
年,卷(期):2024.30(4)
  • 2